tommaso lizzul / Shutterstock.com
The IP landscape in Europe for the CRISPR gene-editing technology is very murky, making it difficult for potential licensees, says Catherine Coombes of HGF.
The continuing interference proceedings in the US concerning clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 systems for gene-editing of eukaryotes have received much media attention. Coverage focuses on two groups: one led by Feng Zhang of the Broad Institute of Harvard University and the Massachusetts Institute of Technology, and the other by Jennifer Doudna of the University of California, Berkeley and Emmanuelle Charpentier of the Helmholtz Centre for Infection Research. The commentary focuses on a potential winner-takes-all scenario.
However, the situation in Europe, where both groups’ patent applications will be examined under a first-to-file system, has received much less media attention. The question remains, which of these two groups will have the underlying rights to CRISPR/Cas9 in Europe? Or will filings by other applicants during this period lead to a more complex early CRISPR/cas9 landscape in Europe?
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Catherine Coombes, HGF, CRISPR, DNA, IP, Broad, licensing, PCT, TPOs,